Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: $TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tarsus Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tarsus Pharmaceuticals's position in the market.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that Bobak Azamian, M.D., Ph.D., CEO and Chairman, will participate in a fireside chat at the 2024 Bank of America Healthcare Conference. The event aims to revolutionize treatment for patients, starting with eye care. The webcast and presentation details are available on the Tarsus website.
Tarsus Pharmaceuticals, Inc. reported a successful first quarter of 2024, with $24.7 million in net product sales of XDEMVY, an 89% increase over the previous quarter. The company delivered approximately 26,000 bottles of XDEMVY to patients, expanded its sales force, secured multiple commercial payer contracts, and strengthened its financial position with a public equity offering and financing commitment. Tarsus remains on-track for broad commercial coverage by the end of 2024 and Medicare coverage in 2025. The company continues to advance its pipeline and engage with the FDA on new treatments. Despite positive revenue growth, Tarsus saw an increase in net loss due to higher expenses, primarily in research and development as well as selling, general, and administrative costs.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) will report its first quarter 2024 financial results on May 8, 2024. The company focuses on unmet needs in eye care. A live webcast will be held to provide the results and a corporate update.